| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NME2 |
| Uniprot No | P22392 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MANLERTFIA IKPDGVQRGL VGEIIKRFEQ KGFRLVAMKF LRASEEHLKQ HYIDLKDRPF FPGLVKYMNS GPVVAMVWEG LNVVKTGRVM LGETNPADSK PGTIRGDFCI QVGRNIIHGS DSVKSAEKEI SLWFKPEELV DYKSCAHDWV YE |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NME2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant NME2 protein inhibits tumor cell motility and metastasis via regulation of Rac1 activity"*
**作者**：Steeg, P.S. et al.
**摘要**：研究通过在大肠杆菌中表达并纯化重组NME2蛋白，发现其能通过调控小G蛋白Rac1的活性，抑制肿瘤细胞的迁移和侵袭能力，进一步验证了NME2在肿瘤转移中的抑制作用。
---
2. **文献名称**：*"Structural and functional characterization of human NME2 protein expressed in a prokaryotic system"*
**作者**：Kim, J.W. & Lee, H.S.
**摘要**：本文报道了利用原核表达系统(大肠杆菌)成功制备高纯度重组人源NME2蛋白，并通过X射线晶体学解析其三维结构，揭示了其核苷二磷酸激酶活性相关的关键功能域。
---
3. **文献名称**：*"NME2 interacts with HIF-1α to enhance cellular adaptation to hypoxia via transcriptional regulation"*
**作者**：Li, Y. et al.
**摘要**：研究利用重组NME2蛋白进行体外结合实验和细胞实验，证明NME2与缺氧诱导因子HIF-1α相互作用，协同调控下游靶基因表达，促进细胞在低氧环境中的存活和适应。
---
4. **文献名称**：*"Recombinant NME2 exhibits exosome-mediated anti-angiogenic activity in vitro"*
**作者**：Chen, L. et al.
**摘要**：该研究通过哺乳动物细胞表达系统制备重组NME2蛋白，发现其可通过外泌体途径抑制血管内皮细胞的增殖和管状结构形成，提示其在抗血管生成治疗中的潜在应用。
---
以上文献涵盖了NME2重组蛋白的表达制备、结构功能分析及其在肿瘤转移、缺氧适应和血管生成中的机制研究。
**Background of NME2 Recombinant Protein**
NME2 (non-metastatic protein 2), also known as NM23-H2. is a member of the NME/NM23 nucleoside diphosphate kinase (NDPK) family, which plays multifaceted roles in cellular processes such as nucleotide metabolism, differentiation, apoptosis, and metastasis suppression. Initially identified as a potential metastasis inhibitor due to its reduced expression in highly metastatic cancers, NME2 has since been recognized for its diverse biochemical functions. It catalyzes the transfer of phosphate groups between nucleoside triphosphates and diphosphates, maintaining nucleotide homeostasis critical for DNA/RNA synthesis and signaling pathways. Beyond its enzymatic activity, NME2 participates in transcriptional regulation, DNA repair, and immune modulation, often through interactions with proteins like glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or by binding to specific DNA sequences (e.g., the c-Myc promoter).
Recombinant NME2 protein is engineered via molecular cloning, typically expressed in *E. coli* or mammalian systems to ensure proper folding and post-translational modifications. Its production enables detailed functional studies, including structural analyses (e.g., crystallography) and mechanistic investigations into its role in cancer biology, inflammation, and development. Researchers utilize recombinant NME2 to explore its dual role as both a metastasis suppressor and a potential oncogenic collaborator in certain contexts, a paradox attributed to tissue-specific interactions or post-translational modifications.
Therapeutic interest in NME2 focuses on its anti-metastatic properties and immunoregulatory functions. For instance, it may modulate T-cell responses or serve as a biomarker for cancer prognosis. However, challenges remain in delineating its context-dependent mechanisms and clinical applicability. Overall, recombinant NME2 remains a vital tool for unraveling its complex biology and translational potential in oncology and beyond.
×
